CovidVax show full list
COVID-19 VACCINE:

RBD replicating influenza vector

researcher:
University of Hong Kong + Xiamen University + Wantai Biopharmaceutical
https://www.hku.hk/
https://en.xmu.edu.cn/
http://www.ystwt.cn/
(China)
vaccine type: Replicating viral vector
Distribution updates
currently no distribution info
Human Testing updates (clinical trials)

PHASE 1

 

started September 1 2020

with 60 healthy volunteers aged 18-60

trial location: Nanjing, Jiangsu, China

» clinical trial details

Sep 10HongKongUni's nasal-spray vaccine will have phase 1 clinical trial recruiting about 100 volunteers (by asiatimes.com)
Animal Testing updates (pre-clinical trials)
currently no pre-clinical trials info
early development updates
currently no early development info



funding:
Coalition for Epidemic Preparedness (CEPI)
Mar 18CEPI will provide $620K to HKU to undertake preclinical testing of their vaccine candidate (by cepi.net)
partnerships:
Sep 09HKU State Key Lab has partnered with Xiamen Uni and Wantai Biopharmaceutical to rapidly develop a vaccine (by hku.hk)



contact | about | ©2020 CovidVax.org project